行业周报：瑞博生物通过港交所IPO聆讯，上市在即-20251228

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the upcoming IPO of Ruibo Bio, which has passed the hearing for listing on the Hong Kong Stock Exchange. The company focuses on innovative siRNA technology platforms targeting various chronic diseases and tumors [4][14] - Ruibo Bio has established multiple technology platforms, including RiboGalSTAR for liver-targeted delivery and RiboOncoSTAR for tumor targeting, with a pipeline that includes over 20 clinical candidates [5][15] - The report emphasizes the potential of the siRNA sector and recommends investment in leading CXO and research service companies, particularly in the innovative drug space [8] Summary by Sections Industry Performance - In the fourth week of December 2025, the pharmaceutical and biotechnology sector declined by 0.18%, underperforming the CSI 300 index by 2.13 percentage points, ranking 25th among 31 sub-industries [7][11] - The raw material drug sector showed the highest increase, rising by 2.05%, while the hospital sector experienced the largest decline, falling by 2.82% [31] Company Developments - Ruibo Bio has seven siRNA pipelines in clinical research, with its core product RBD4059 being the first siRNA drug for treating thrombotic diseases currently in Phase 2 clinical trials [5][14] - The company plans to advance 2-4 new candidates into clinical stages annually, supported by significant partnerships with major pharmaceutical companies, reflecting recognition of its R&D capabilities [6][22] Investment Recommendations - The report recommends focusing on innovative drugs and their supply chains, particularly in the small nucleic acid space, and suggests a monthly investment portfolio including companies like Sangamo Therapeutics and Innovent Biologics [8]